Therapeutic Advances in Respiratory Disease This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy
Conclusion: Tiotropium + olodaterol Respimat® FDC is a cost-effective bronchodilator in the maintenance treatment of COPD for the Italian health care system. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Selya-Hammer, C., Gonzalez-Rojas Guix, N., Baldwin, M., Ternouth, A., Miravitlles, M., Rutten-van Mölken, M., Goosens, L. M. A., Buyukkaramikli, N., Acciai, V. Tags: Original Research Source Type: research

Use of varenicline for more than 12 months for smoking cessation in heavy chronic obstructive pulmonary disease smokers unmotivated to quit: a pilot study
Conclusions: Use of varenicline for more than the traditional 12 recommended weeks may be a good strategy to increase the cessation rate in heavy smokers with mild COPD. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Sansores, R. H., Ramirez-Venegas, A., Arellano-Rocha, R., Noe-Diaz, V., Garcia-Gomez, L., Perez Bautista, O., Velazquez Uncal, M. Tags: Original Research Source Type: research

Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience
Telavancin (TLV) is a lipoglycopeptide derivative of vancomycin (VAN), which has activity against Gram-positive aerobic bacteria, and is especially effective against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria resistant to VAN. Comparative clinical studies of TLV have demonstrated noninferiority compared with VAN in the treatment of hospital-acquired Gram-positive pneumonia, with high cure rates for TLV-treated patients with monomicrobial S. aureus infection, including isolates with reduced VAN susceptibility. The results based on the patients’ clinical response were supported by sup...
Source: Therapeutic Advances in Respiratory Disease - July 19, 2016 Category: Respiratory Medicine Authors: Liapikou, A., Dimakou, K., Toumbis, M. Tags: Reviews Source Type: research

Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness
Influenza infection is an important cause of global mortality and morbidity with the greatest impact on older people and those with chronic disease. Patients with chronic obstructive pulmonary disease (COPD) are particularly vulnerable to influenza, with evidence for increased incidence and severity of infection. In this patient group influenza is associated with exacerbations and pneumonia which result in a significant healthcare burden and premature mortality. Influenza vaccination and in particular the use of the seasonal trivalent influenza vaccine (TIV) is recommended for patients with COPD. The evidence base for its ...
Source: Therapeutic Advances in Respiratory Disease - July 19, 2016 Category: Respiratory Medicine Authors: Sanei, F., Wilkinson, T. Tags: Reviews Source Type: research

Risk factors and management of oligometastatic non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is an aggressive malignancy with close to half of all patients presenting with metastatic disease. A proportion of these patients with limited metastatic disease, termed oligometastatic disease, have been shown to benefit from a definitive treatment approach. Synchronous and metachronous presentation of oligometastatic disease have prognostic significance, with current belief that metachronous disease is more favorable. Surgical excision of intracranial and extracranial oligometastatic disease has been shown to improve survival, especially in patients with lymph node-negative disease, ade...
Source: Therapeutic Advances in Respiratory Disease - July 19, 2016 Category: Respiratory Medicine Authors: Patel, A. N., Simone, C. B., Jabbour, S. K. Tags: Reviews Source Type: research

A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma
Conclusions: FP/FORM improved lung function and measures of asthma control with comparable efficacy to FP/SAL, and demonstrated a favourable safety and tolerability profile in children aged 4–12 years. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - July 19, 2016 Category: Respiratory Medicine Authors: Emeryk, A., Klink, R., McIver, T., Dalvi, P. Tags: Original Research Source Type: research

Aspirin use and the risk of bleeding complications after therapeutic bronchoscopy
Conclusion: Aspirin use was not associated with increased risk of bleeding or procedure-related complications after therapeutic bronchoscopy. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - July 19, 2016 Category: Respiratory Medicine Authors: Harris, K., Kebbe, J., Modi, K., Alraiyes, A. H., Kumar, A., Attwood, K., Dhillon, S. S. Tags: Original Research Source Type: research

Emergency management for congenital tracheal stenosis with endoluminal stenting in pediatric intensive care units
Conclusion: Airway stenting may provide an important therapeutic option in infants with CTS. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - July 19, 2016 Category: Respiratory Medicine Authors: Xu, X., Ding, H., Liu, X., Zhu, B., Feng, Z. Tags: Original Research Source Type: research

Development of a novel image-based program to teach narrow-band imaging
Conclusions: The overall class average normalized gain of 32% shows our test can be used to improve trainees’ competency in analyzing NBI Images. The testing method (and tool) can be used to measure the follow up 4 weeks later. Better follow-up test results would be expected with more frequent practice by trainees after the course. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - July 19, 2016 Category: Respiratory Medicine Authors: Dumas, C., Fielding, D., Coles, T., Good, N. Tags: Original Research Source Type: research

Diagnostic yield of electromagnetic navigational bronchoscopy
Conclusion: In our cohort, diagnostic yield was 60% with a 6% pneumothorax rate. A suggestive trend for the presence of bronchus sign on computed tomography scan, albeit statistically nonsignificant, as a predictor for improved diagnostic yield needs to be validated in a larger cohort. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - July 19, 2016 Category: Respiratory Medicine Authors: Al-Jaghbeer, M., Marcus, M., Durkin, M., McGuire, F. R., Iftikhar, I. H. Tags: Original Research Source Type: research

Corrigendum
Maltais, F., Singh, S., Donald, A., Crater, G., Church, A., Goh, A. et al. (2014) Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis 8: 169–181. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - June 1, 2016 Category: Respiratory Medicine Tags: Corrigendum Source Type: research

Malignant pleural mesothelioma: an update on diagnosis and treatment options
Malignant pleural mesothelioma (MPM) represents a significant diagnostic and therapeutic challenge and is almost always a fatal disease. Imaging abnormalities are common, but have a limited role in distinguishing mesothelioma from metastatic pleural disease. Similarly, minimally invasive biomarkers have shown promise but also have limitations in the diagnosis of mesothelioma. In experienced centers, cytology and immunohistochemistry are now sufficient to diagnose the epithelioid subtype of mesothelioma, which can reduce the need for more invasive diagnostic investigations. Prognosis of MPM is modestly impacted by oncologic...
Source: Therapeutic Advances in Respiratory Disease - June 1, 2016 Category: Respiratory Medicine Authors: Kondola, S., Manners, D., Nowak, A. K. Tags: Reviews Source Type: research

Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations
With the advancement in understanding the biology of non-small cell lung cancer (NSCLC), therapies focused on novel molecular pathways have come to the forefront of NSCLC treatment. This review focuses on the preclinical and clinical aspects underlying the targeting of RAS aberrations in NSCLC with special focus on MEK inhibitors which work by inhibiting the principal downstream mediator of RAS aberrations with a view on how to optimize outcomes with these agents. Preclinical evidence of the activity of MEK inhibitors in KRAS-mutant NSCLC has pushed forward the clinical development of these agents (namely selumetinib and t...
Source: Therapeutic Advances in Respiratory Disease - June 1, 2016 Category: Respiratory Medicine Authors: Abdel-Rahman, O. Tags: Reviews Source Type: research

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
First-line afatinib significantly improved progression-free survival, patient-reported outcomes, and quality of life compared with chemotherapy regimens in patients with advanced epidermal-growth-factor-receptor (EGFR) mutation-positive non-small cell lung cancer, based on results of the LUX-Lung 3 and LUX-Lung 6 trials. When the analysis of these trials was restricted to patients with common EGFR mutations only (exon 19 deletions and L858R), the advantage over chemotherapy was even more pronounced. A significant overall survival advantage was firstly demonstrated versus chemotherapy in patients with non-small cell lung ca...
Source: Therapeutic Advances in Respiratory Disease - June 1, 2016 Category: Respiratory Medicine Authors: Ke, E.-E., Wu, Y.-L. Tags: Reviews Source Type: research

Inhaled corticosteroids and the increased risk of pneumonia: whats new? A 2015 updated review
There is a considerable amount of evidence that supports the possibility of an increased risk of pneumonia associated with prolonged use of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD). However, as yet, no statistically significant increase in pneumonia-related 30-day mortality in patients on ICS has been demonstrated. The lack of objective pneumonia definitions and radiological confirmations have been a major source of bias, because of the similarities in clinical presentation between pneumonia and acute exacerbations of COPD. One of the newer fluticasone furoate studies over...
Source: Therapeutic Advances in Respiratory Disease - June 1, 2016 Category: Respiratory Medicine Authors: Iannella, H., Luna, C., Waterer, G. Tags: Reviews Source Type: research